Cagrilintide is an analog of amylin – a pancreatic hormone that induces satiety. The aim of this study is to investigate the effects of cagrilintide on body weight, safety and tolerability. The researchers conducted a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial in 57 health care centers of 10 countries. Participants were over 18 years without diabetes but were overweight or obese. The results show that cagrilintide treatment was effective in reducing body weight of over-weighed and obese people and was also well-tolerated, which supports the development of new mechanisms for weight management.